The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Outcomes of outpatient tisa-cel recipients with B-NHL
Nausheen Ahmed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the outcomes of outpatient tisagenlecleucel (tisa-cel) treatment for B-cell non-Hodgkin lymphoma (B-NHL). Dr Ahmed comments on the safety and efficacy of outpatient tisa-cel administration, emphasizing the importance of a well-established infrastructure and robust patient support. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite: consulting, BMS: advisory board
